No phaseCompleted
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging
- Sponsor
- Steven E Arnold, MD (Academic or other)
- Enrolment
- 61 enrolled
- Conditions
- Cognition Disorders in Old Age; Mild Cognitive Impairment; Cognitive Decline
- Interventions
- Niagen; Placebo Comparator
- Ages
- adults, older adults
- Registry
- NCT04078178
From the registry
In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).
Primary outcomes
- The Effect of Niagen vs PBO on Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).